Research programme: anti-inflammatories - TransCell Therapeutics

Drug Profile

Research programme: anti-inflammatories - TransCell Therapeutics

Latest Information Update: 31 Mar 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TransCell Therapeutics
  • Class Peptides
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Adult respiratory distress syndrome; Age-related macular degeneration; Atopic dermatitis; Crohn's disease; Diabetic retinopathy; Hepatitis; Inflammatory bowel diseases; Ocular inflammation; Psoriasis; Scleroderma; Sepsis; Ulcerative colitis

Most Recent Events

  • 27 Aug 2003 Preclinical trials in Age-related macular degeneration in USA (Ophthalmic)
  • 27 Aug 2003 Preclinical trials in Atopic dermatitis in USA (Topical)
  • 27 Aug 2003 Preclinical trials in Crohn's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top